NCT02492711: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

NCT02492711
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patient must have received at least 2 prior lines of anti-HER2 directed therapy in the metastatic setting; Patient must have prior treatment with at least one, & no more than three, lines of therapy overall in the metastatic setting
Exclusions: Patients with known untreated brain metastasis
https://ClinicalTrials.gov/show/NCT02492711

Comments are closed.

Up ↑